SynthesisNature genetics2014
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.
Registry-linked trialAbstract readMeta-Analysis
In one paragraph
Synthesis in Nature genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01351467 (Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives), which is not on this map. Cited by 1,130 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,130citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives
Who cites it
1,130 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Causal Association Between Sedentary Behaviors and Health Outcomes: A Systematic Review and Meta-Analysis of Mendelian Randomization Studies.Sports medicine (Auckland, N.Z.) · 2024Pooled it
- MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.Journal of gastroenterology · 2024Pooled it
- LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.Nature medicine · 2026Trial
- Genetic findings in a Turkish clinical cohort with hereditary Parkinson's disease.Neurogenetics · 2026Article
- Cellular and systemic modifiers of alpha-synuclein proteostasis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026Review
- Condensate-driven triglyceride reduction links α-synuclein to mitochondrial dysfunction.EMBO reports · 2026Article
- A new era of genome-wide association studies in the field of Alzheimer's disease and overlapping co-pathologies: lessons learned from a neuropathology-centered approach.Acta neuropathologica · 2026Review
- Ion transport as a determinant of membrane fusion and fission.Nature structural & molecular biology · 2026Review
- Individualized Bayesian Inference Identifies Novel Genetic Variants for Parkinson's Disease.Genetic epidemiology · 2026Article
- Rare Variants May Influence Disease Risk and Clinical Features in Sporadic Late-Onset Chinese Parkinson's Disease Patients.International journal of molecular sciences · 2026Article
- Neuronal titration of Snca via enhancer disruption mitigates disease onset in a Parkinson's disease mouse model.Brain : a journal of neurology · 2026Article
- Epigenetic Mechanisms Underlying Cognitive Dysfunction in Parkinson's Disease: Current Evidence and Future Prospects.Brain and behavior · 2026Review
- Spatial multi-omics identifies early synaptic pruning and context-specific dopaminergic vulnerability in synucleinopathies.Nature communications · 2026Article
- Rewiring Lipid Metabolism: PINK1 as a Central Regulator of Mitochondrial Homeostasis in Parkinson's Disease.International journal of molecular sciences · 2026Review
- A human lysosomal storage disorder toolkit for decoding proteome landscapes in cortical-like and dopaminergic-like induced neurons.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Exploring MAPT-containing H1 and H2 haplotypes in Parkinson's disease across diverse populations.NPJ Parkinson's disease · 2026Article
- Article
- The Association Between Alzheimer's Disease-Related Biomarkers And Parkinson's Disease Based On Single-Cell Sequencing Analysis Combined With Mendelian Randomization.Journal of molecular neuroscience : MN · 2026Article
- Astrocytic ACSBG1 depletion improves lipid-cytokine signaling and attenuates α-Synuclein pathology in a Parkinson's disease mouse model.bioRxiv : the preprint server for biology · 2026Article
- A genome-wide association study of young onset Parkinson's disease in European ancestry.medRxiv : the preprint server for health sciences · 2026Article
1,070 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
59 authors.
Mike A Nalls1] Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA. [2].
Nathan Pankratz1] Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA. [2].
Christina M Lill1] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] Department of Neurology, Focus Program Translational Neuroscience, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Chuong B Do23andMe, Inc., Mountain View, California, USA.
Dena G Hernandez1] Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA. [2] Reta Lila Weston Institute, University College London Institute of Neurology, Queen Square, London, UK.
Mohamad Saad1] Department of Biostatistics, University of Washington, Seattle, Washington, USA. [2] INSERM, UMR 1043, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France. [3] Paul Sabatier University, Toulouse, France.
Anita L DeStefano1] Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA. [2] Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. [3] National Heart, Lung, and Blood Institute (NHLBI) Framingham Heart Study, Framingham, Massachusetts, USA.
Eleanna KaraDepartment of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Jose BrasDepartment of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Manu Sharma1] Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany. [2] Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Claudia SchulteDepartment for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Margaux F KellerLaboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.
Sampath ArepalliLaboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.
Christopher LetsonLaboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.
Connor EdsallLaboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.
Hreinn StefanssondeCODE Genetics, Reykjavík, Iceland.
Xinmin LiuDepartment of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA.
Hannah PlinerLaboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.
Joseph H LeeThe Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA.
Rong ChengThe Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA.
International Parkinson's Disease Genomics Consortium (IPDGC)
Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI)
23andMe
GenePD
NeuroGenetics Research Consortium (NGRC)
Hussman Institute of Human Genomics (HIHG)
Ashkenazi Jewish Dataset Investigator
Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE)
North American Brain Expression Consortium (NABEC)
United Kingdom Brain Expression Consortium (UKBEC)
Greek Parkinson's Disease Consortium
Alzheimer Genetic Analysis Group
M Arfan Ikram1] Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. [2] Department of Radiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. [3] Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
John P A IoannidisStanford Prevention Research Center, Stanford University, Stanford, California, USA.
Georgios M HadjigeorgiouNeuroscience Unit, Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Joshua C BisCardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA.
Maria Martinez1] INSERM, UMR 1043, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France. [2] Paul Sabatier University, Toulouse, France.
Joel S Perlmutter1] Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA. [2] Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA. [3] Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Alison Goate1] Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, USA. [2] Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA. [3] Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. [4] Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.
Karen Marder1] The Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA. [2] Gertrude H. Sergievsky Center, Columbia University Medical Center, New York, New York, USA. [3] Department of Neurology, Columbia University Medical Center, New York, New York, USA. [4] Department of Psychiatry, Columbia University Medical Center, New York, New York, USA.
Brian FiskeThe Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
Margaret SutherlandNeuroscience Center, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
Georgia Xiromerisiou1] Neuroscience Unit, Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece. [2] Department of Neurology, Papageorgiou Hospital, Thessaloniki, Greece.
Richard H MyersDepartment of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.
Lorraine N Clark1] Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA. [2] The Taub Institute for Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, USA.
Kari StefanssondeCODE Genetics, Reykjavík, Iceland.
John A HardyReta Lila Weston Institute, University College London Institute of Neurology, Queen Square, London, UK.
Peter HeutinkGenome Biology for Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Honglei ChenEpidemiology Branch, National Institute of Environmental Health Sciences, US National Institutes of Health, Research Triangle, North Carolina, USA.
Nicholas W WoodDepartment of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Henry HouldenDepartment of Molecular Neuroscience, Institute of Neurology, University College London, London, UK.
Haydeh PayamiNew York State Department of Health Wadsworth Center, Albany, New York, USA.
Alexis Brice1] Sorbonne Université, UPMC Université Paris 06, UM 75, INSERM U1127, Institut du Cerveau et de la Moelle, Paris, France. [2] CNRS, UMR 7225, Paris, France. [3] Pitié-Salpêtrière Hospital, Department of Genetics and Cytogenetics, Paris, France.
William K ScottDepartment of Human Genetics, University of Miami School of Medicine, Miami, Florida, USA.
Thomas GasserDepartment for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Lars Bertram1] Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany. [2] School of Public Health, Faculty of Medicine, The Imperial College of Science, Technology and Medicine, London, UK.
Nicholas Eriksson23andMe, Inc., Mountain View, California, USA.
Tatiana ForoudDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Andrew B SingletonLaboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA.
Funding
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MCTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0MTransgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4MUnderstanding Mechanisms of a-synuclein pathologyP50NS038377 · NINDS · JOHNS HOPKINS UNIVERSITY · PI DAWSON, TED M. · 1998 to 2019
$38.8MThe National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS)U24AG056270 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gary Wayne Beecham, TATIANA M. FOROUD · 2017 to 2026
$31.4MNeuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1MQuality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2MIndiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3MPRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9MUniversity of Pittsburgh Clinical and Translational Science InstitutionKL2RR024154 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$22.2MEPIDEMIOLOGY OF DEMENTIA IN THE FRAMINGHAM STUDYR01AG008122 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, SESHADRI, SUDHA · 1989 to 2015
$14.4MIntramural NIH HHS Z01 AG000932Intramural NIH HHS Z01 AG000949Medical Research Council G0700943Medical Research Council G0701075Medical Research Council G0802462Medical Research Council G0802760Medical Research Council G0901254Medical Research Council G1001253Medical Research Council G108/638Medical Research Council G1100479Medical Research Council G1100643Medical Research Council MC_G0901330Medical Research Council MC_G1000735Medical Research Council MC_PC_09003Medical Research Council MR/J004758/1Medical Research Council MR/L010305/1Medical Research Council MR/L016400/1Medical Research Council MR/L501554/1NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1TR000124NCATS NIH HHS UL1 TR001108NCI NIH HHS R01CA141668NCRR NIH HHS 1KL2RR024154NCRR NIH HHS 2UL1 RR024156NHGRI NIH HHS R44 HG006981NHLBI NIH HHS R01 HL120393NIA NIH HHS AG023629NIA NIH HHS AG025259NIA NIH HHS AG031287NIA NIH HHS AG033193NIA NIH HHS AG08122NIA NIH HHS AG16495NIA NIH HHS P30AG013846NIA NIH HHS P30AG024826NIA NIH HHS R01 AG041797NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG056270NIDDK NIH HHS DK063491NINDS NIH HHS 1K23NS070867NINDS NIH HHS K02 NS073836NINDS NIH HHS NS036630NINDS NIH HHS NS050487NINDS NIH HHS NS060113NINDS NIH HHS NS17950NINDS NIH HHS P50 NS038377NINDS NIH HHS P50 NS071674NINDS NIH HHS P50NS071674NINDS NIH HHS R01NS037167NINDS NIH HHS R01 NS075321NINDS NIH HHS R01 NS076843NINDS NIH HHS R01 NS088538NINDS NIH HHS R01-NS-36960NINDS NIH HHS U01 NS082151Parkinson's UK F-1202Parkinson's UK G-0907Parkinson's UK G-0909Parkinson's UK J-0804Wellcome Trust 076113Wellcome Trust 083948/Z/07/ZWellcome Trust 085475Wellcome Trust 089698Wellcome Trust 090355Wellcome Trust WT089698/Z/09/Z
Abstract
We conducted a meta-analysis of Parkinson's disease genome-wide association studies using a common set of 7,893,274 variants across 13,708 cases and 95,282 controls. Twenty-six loci were identified as having genome-wide significant association; these and 6 additional previously reported loci were then tested in an independent set of 5,353 cases and 5,551 controls. Of the 32 tested SNPs, 24 replicated, including 6 newly identified loci. Conditional analyses within loci showed that four loci, including GBA, GAK-DGKQ, SNCA and the HLA region, contain a secondary independent risk variant. In total, we identified and replicated 28 independent risk variants for Parkinson's disease across 24 loci. Although the effect of each individual locus was small, risk profile analysis showed substantial cumulative risk in a comparison of the highest and lowest quintiles of genetic risk (odds ratio (OR) = 3.31, 95% confidence interval (CI) = 2.55-4.30; P = 2 × 10(-16)). We also show six risk loci associated with proximal gene expression or DNA methylation.
Indexed as
Genetic LociCase-Control StudiesGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansParkinson DiseasePolymorphism, Single NucleotideRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01351467ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.